Use of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Management of Patients and Practical Applications for Pharmacy Practitioners

Abstract

Spanish

French

OBJECTIVE:

To summarize the use of tyrosine kinase inhibitors (TKIs) for treatment of patients with chronic myeloid leukemia (CML) and provide practical information for patient management.

DATA SOURCES:

Literature was retrieved from PubMed (2000-January 2011), using the search terms chronic myeloid leukemia and tyrosine kinase inhibitor. Abstracts presented at the 2008-2010 annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, reference citations from identified publications, as well as the manufacturers' full prescribing information for cited drugs, also were reviewed.

STUDY SELECTION AND DATA EXTRACTION:

Articles evaluating the efficacy and safety of the TKIs imatinib, nilotinib, and dasatinib were evaluated. Focus was placed on publications supporting management of patients with CML in the chronic phase. Reports presenting clinical trial information of TKIs in development also were included.

DATA SYNTHESIS:

The discovery of targeted tyrosine kinase inhibition of BCR-ABL kinase dramatically changed the treatment of CML. Imatinib, the first TKI approved for treatment of patients with Philadelphia chromosome-positive CML, demonstrated significant superiority over the previous standard of care: interferon plus cytarabine. The newer, more potent TKIs, nilotinib and dasatinib, have demonstrated improved efficacy over imatinib as first-line therapy and provide an effective option for patients with resistance or intolerance to imatinib.

CONCLUSIONS:

To maximize efficacy of TKI therapy, close patient management, involving frequent monitoring of patient response, is essential. Given the importance of continuing TKI therapy, early recognition and management of adverse events are critical to optimizing outcomes in patients with CML. In addition to the safety profile and considerations of comorbidities, additional factors can affect therapeutic selection, including drug-drug and drug-food interactions. Research investigating new therapies, particularly for patients harboring the ***T315 mutation—which remains refractory to current TKIs—continues in the quest to improve outcomes in patients with CML.

Keywords

chronic myeloid leukemia dasatinib imatinib nilotinib

Get full access to this article

View all access options for this article.

References

Altekruse

Kosary

Krapcho

SEER Cancer Statistics Review, 1975-2007, National Cancer Institute 2010. http://seer.cancer.gov/statfacts/html/cmyl.html (accessed 2010 Nov 9).

Perrotti

Jamieson

Goldman

Skorski

. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010;120:2254–64. DOI 10.1172/JCI4124641246.

Kalidas

Kantarjian

Talpaz

. Chronic myelogenous leukemia. JAMA 2001;286:895–8.

CML Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997;89:1616–20.

Deininger

. Resistance and relapse with imatinib in CML: causes and consequences. J Natl Compr Canc Netw 2008;6(suppl 2):S11–21.

Deininger

O'Brien

Guilhot

International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract). Blood (ASH Annual Meeting Abstracts) 2009;114:1126.

O'Brien

Guilhot

Goldman

International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) (abstract). Blood (ASH Annual Meeting Abstracts) 2008;112:186.

O'Brien

Guilhot

Larson

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004. DOI 10.1056/NEJMoa022457348/11/994.

Druker

Guilhot

O'Brien

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–17. DOI 10.1056/NEJMoa062867.

10.

Weisberg

Manley

Mestan

Cowan-Jacob

Ray

Griffin

. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765–9. DOI 10.1038/sj.bjc.6603170.

11.

Osborn

Hughes

. Managing imatinib resistance in chronic myeloid leukaemia. Curr Opin Hematol 2010;17:97–103. DOI 10.1097/MOH.0b013e3283366bcb.

12.

Lombardo

Lee

Chen

. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–61.

13.

Novartis Pharmaceuticals. Risk Evaluation and Mitigation Strategy (REMS): Tasigna (nilotinib). 2010:1–57. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s001REMS.pdf (accessed 2011 Feb 11).

14.

Prescribing information. Tasigna (nilotinib). Hanover, NJ: Novartis Pharmaceuticals, 2010.

15.

Prescribing information. Sprycel (dasatinib). Princeton, NJ: Bristol Myers Squibb Company, 2010.

16.

Apperley

. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 2009;7:1050–8.

17.

Cortes

Kim

Raffoux

Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176–83. DOI 10.1038/leu.2008.221.

18.

Hochhaus

Kantarjian

Baccarani

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303–9. DOI 10.1182/blood-2006-09-047266.

19.

Kantarjian

Pasquini

Levy

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136–47. DOI 10.1002/cncr.24504.

20.

Mauro

Baccarani

Cervantes

Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) (abstract). J Clin Oncol (Meeting Abstracts) 2008;26:7009.

21.

Kantarjian

Cortes

Kim

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322–9. DOI 10.1182/blood-2008-11-186817.

22.

Shah

Kantarjian

Kim

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–12. DOI 10.1200/JCO.2007.14.9260.

23.

Kantarjian

Giles

Gattermann

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–6. DOI 10.1182/blood-2007-03-080689.

24.

Kantarjian

Giles

Bhalla

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141–5. DOI 10.1182/blood-2010-03-277152.

25.

Kantarjian

Shah

Hochhaus

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–70. DOI 10.1056/NEJMoa1002315.

26.

Shah

Kantarjian

Hochhaus

Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up (abstract). Blood 2010;116:206.

27.

Saglio

Kim

Issaragrisil

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–9. DOI 10.1056/NEJMoa0912614.

28.

Hughes

Hochhaus

Saglio

ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) (abstract). Blood 2010;116:207.

29.

Hughes

Hochhaus

Saglio

ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) (oral presentation). Presented at: American Society of Hematology, Orlando, FL, 2010.

30.

NCCN. National Comprehensive Cancer Network: clinical practice guidelines in oncology. Chronic myelogenous leukemia. Version 2. 2011:1–63. http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf (accessed 2011 Jan 24).a.

31.

Baccarani

Cortes

Pane

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–51. DOI 10.1200/JCO.2009.25.0779.

32.

Faderl

Talpaz

Estrov

Kantarjian

. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207–19.

33.

Clark

. Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. Leuk Res 2009;33:1151–5. DOI 10.1016/j.leukres.2009.04.001.

34.

Baccarani

Saglio

Goldman

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–20. DOI 10.1182/blood-2006-02-005686.

35.

Alvarado

Kantarjian

O'Brien

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009;115:3709–18. DOI 10.1002/cncr.24418.

36.

Muller

Hochhaus

Lauseker

Molecular response <1% BCR-ABL IS at 12 months is associated with improved overall and progression-free survival: the randomized german CML-study IV (abstract). Blood 2010;116:669.

37.

Marin

Bazeos

Mahon

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–8. DOI 10.1200/JCO.2009.26.3087.

38.

Noens

van Lierde

De Bock

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401–11. DOI 10.1182/blood-2008-12-196543.

39.

Johnson

Beaulieu

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61–9. DOI 10.1185/03007990903396469.

40.

St. Charles

Bollu

Hornyak

Coombs

Blanchette

DeAngelo

. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia (abstract). Blood 2009;114:2209.

41.

Williams

Garcia-Gonzalez

Ault

Symptom burden in patients with chronic myeloid leukemia (CML) on kinase inhibitor (KI) therapy (abstract). Blood 2010;116:3838.

42.

Atallah

Durand

Kantarjian

Cortes

. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233–7. DOI 10.1182/blood-2007-01-070144.

43.

Salie

Silver

. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2010;10:331–5. DOI 10.3816/CLML.2010.n.065.

44.

Kantarjian

Giles

Bhalla

Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes (abstract). Blood 2009;114:1129.

45.

Kantarjian

Giles

Hochhaus

Nilotinib in patients with imatinib-resistant or-intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results (abstract). J Clin Oncol 2008;26:7010.

46.

Masiello

Gorospe

3rd Yang

. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;2:46. DOI 10.1186/1756-8722-2-46.

47.

Deininger

O'Brien

Ford

Druker

. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637–47. DOI 10.1200/JCO.2003.11.143JCO.2003.11.143.

48.

van Erp

Gelderblom

Guchelaar

. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692–706. DOI S0305-7372(09)00116-9 [pii]10.1016/j.ctrv.2009.08.004.

49.

Tinsley

. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. J Clin Nurs 2010;19:1207–18. DOI 10.1111/j.1365-2702.2009.03167.x.

50.

Ault

Kantarjian

O'Brien

Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204–8. DOI 10.1200/JCO.2005.04.6557.

51.

Golas

Arndt

Etienne

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375–81.

52.

Kimura

Naito

Segawa

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106:3948–54. DOI 10.1182/blood-2005-06-2209.

53.

Gambacorti-Passerini

Kim

D-W

Kantarjian

An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia (abstract). Blood 2010;116:208.

54.

Yokota

Kimura

Masuda

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306–14. DOI 10.1182/blood-2006-03-013250.

55.

Giles

Cortes

Jones

Bergstrom

Kantarjian

Freedman

. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500–2. DOI 10.1182/blood-2006-05-025049.

56.

Smith

Britten

Clary

Nguyen

Woodward

Hurwitz

. A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 2009;27:3512.

57.

Smith

Britten

Garon

A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma (abstract). ASCO Meeting Abstracts 2010;28:3105.

58.

Cortes

Talpaz

Bixby

A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings (abstract). Blood 2010;116:210.

59.

Legros

Hayette

Nicolini

BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

Leukemia 2007;21:2204–6.

60.

Cortes

Wetzler

Lipton

Subcutaneous omacetaxine (OM) treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure (abstract). Blood 2010;116:2290.

61.

Weisberg

Catley

Wright

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109:2112–20. DOI 10.1182/blood-2006-06-026377.

62.

O'Hare

Walters

Stoffregen

. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–5. DOI 10.1158/0008-5472.CAN-05-0259.